Skip to content
DataLookout
Menu

NCT05268107

Ethnic Differences in Mechanisms of Action of Dupilumab

StatusRecruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved at least 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 2026 to Jul 2027
    • Eligibility criteria expanded, about 24 words
    • Study completion pushed from Jun 2027 to Jan 2028
  2. Notable Primary completion date: Dec 2025 to Dec 2026
    • Study completion date: Jun 2026 to Jun 2027
    v8
  3. Notable Primary completion date: Dec 2024 to Dec 2025
    • Study completion date: Jun 2025 to Jun 2026
    v7
  4. Notable Primary completion date: Dec 2023 to Dec 2024
    • Study completion date: Apr 2024 to Jun 2025
    v6
  5. Minor Start date changed from estimate of Jan 2023 to Jan 25, 2023v5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Start date: Oct 2022 to Jan 2023v4
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: May 2022 to Oct 2022
    • Site details revised
    v3
  3. Notable Start date: Mar 2022 to May 2022v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin4 (IL4) from week 0 to 2.
Timeframe: Week 0, week 2

Secondary (7)

Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin13 from week 0 to 2.
Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of Interferon (IFN) from week 0 to 2.
Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin36 from week 0 to 2.
Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin4 from week 0 to 16.
Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin13 from week 0 to 16.
Show 2 moreShow less
Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of IFN from week 0 to 16.
Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin36 from week 0 to 16.

Arms and interventions

DupilumabExperimental

The 3 groups of patients (Asian, African American, and Caucasian) will all receive the same intervention.

Drugs: Dupilumab

Sites

1 site in 1 country

  • University of MichiganAnn Arbor, Michigan, United States